Cost-utility analysis of dapagliflozin in patients with chronic kidney disease
Objective:To evaluate the long-term economics of dapagliflozin for chronic kidney disease since a large randomized controlled trial has confirmed the efficacy and safety of dapagliflozin in patients with chronic kidney disease.Therefore it is necessary to evaluate the economic efficacy of dapagliflozin in the treatment of chronic kidney disease.Methods:Based on Markov model,the economics of adding dapagliflozin for chronic kidney disease was evaluated from the payer's perspective.Markov model parameters came from published clinical and economic literature.Model cycle was one year.Simulate lifelong direct medical expenses and quality adjusted life years(QALYs).One-way and probabilistic sensitivity analysis was used to check the robustness.Results:Markov model cohort analysis showed that in the dapagliflozin group,the patients could acquire 13.70 QALYs with 0.3381 million yuan while the conventional group would benefit 13.37 QALYs with 0.371 5 million yuan.The sensitive analysis showed that the result was robust.Conclusion:Compared with the conventional treatment,adding dapagliflozin may be a better choice in the long run for chronic kidney disease.
chronic kidney diseasedapagliflozinpharmacoeconomic evaluationMarkov model
NETL
NSTL
万方数据
维普
